ADMC Publications

Nho K, Kueider-Paisley A, Ahmad S, et al. Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers. JAMA Netw Open.Published online July 31, 20192(7):e197978. https://doi:10.1001/jamanetworkopen.2019.7978

Arnold M, Nho K, Kueider-Paisley A, Massaro T, Brauner B, Mahmoudiandehkordi S, Louie G, Moseley A, Thompson J, St. John-Williams L, Tenenbaum J, Blach C, Chang R, Brinton D, Baillie R, Han X, Trojanowski J, Shaw L, Weiner M, Trushina E, Toledo J, Krumsiek J, Doraiswamy P, Saykin A, Kaddurah-Daouk R, Kastenmuller G, Alzheimers Disease Neuroimaging Initiative, Alzheimers Disease Metabolomics Consortium. The Alzheimer’s Disease Metabolome: Effects of Sex and APOE ϵ4 genotype. bioRxiv 585455; doi: https://doi.org/10.1101/585455

Mahmoudiandehkordi S, Arnold M, Nho K, Ahmad S, Jia W, Xia, Louie G, Kueider A, Moseley M, Thompson W, St. John Williams L, Tenenbaum J, Blach C, Baillie R, Han X, Bhattacharyya S, Toledo T, Schafferer S, Klein S, Koal S, Risacher S, Kling M, Motsinger-Reif A, Rotroff D, Jack J, Hankemeier T, Bennett D, De Jager P, Trojanowski J, Shaw L, Weiner M, Doraiswamy P. M., van Duijn C, Saykin A, Kastenmueller, G. and Kaddurah-Daouk R. Altered Bile Acid Profile Associates with Cognitive Impairment in Alzheimer’s Disease: An Emerging Role for Gut Microbiome. Alzheimers Dement. 2019; 15(1):76-92. https://www.ncbi.nlm.nih.gov/pubmed/30337151

Nho K, Kueider-Paisley A, MahmoudianDehkordi S, Arnold M, Risacher S, Louie G, Blach C, Baillie R, Han X, Kastenmueller G, Jia W, Xie G, Ahmad S, Hankemeier T, van Duijn C. M. ,  Trojanowski J, Shaw L, Weiner M, Doraiswamy P. M., Saykin  A., and Kaddurah-Daouk R . Altered Bile Acid Profile in Mild Cognitive Impairment and Alzheimer’s Disease: Relationship to Neuroimaging and CSF Biomarkers. Alzheimers Dement. 2019; 15(2):232-44. https://www.ncbi.nlm.nih.gov/pubmed/30337152

Barupal D, Baillie R, Fan S, Saykin A, Meikle P, Nho K, Arnold M, Fiehn O, Kaddurah-Daouk R. Sets of Co-regulated Serum Lipids are Associated with Alzheimer Disease Pathology. 2019.

Bernath M, Bhattacharyya S, Nho K, Barupal D, Fiehn O, Baillie R, Risacher S, Arnold M, Jacobson T. Trojanowsli J, Shaw L, Weiner M, Kaddurah-Daouk R, Saykin A. Serum triglycerides in Alzhiemer’s disease: Relation to neuroimaging and CSF biomarkers. 2018.

Varma VR, Oommen AM, Varma S, Casanova R, An Y, Andrews RM, O’Brien R, Pletnikova O, Troncoso JC, Toledo J, Baillie R, Arnold M, Kastenmueller G, Nho K, Doraiswamy PM, Saykin AJ, Kaddurah-Daouk R, Legido-Quigley C, Thambisetty M. Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. PLoS Med. 2018;15(1)(3). https://doi.org/10.1371/journal.pmed.1002482

Kaddurah-Daouk R. Genomics and imaging data informed metabolomics: A biochemical roadmap for Alzheimer disease. Alzheimers Dement. 2017: 13(7); 542. doi: https://doi.org/10.1016/j.jalz.2017.07.129

Toledo JB, Arnold M, Kastenmuller G, Chang R, Baillie RA, Han XL, Thambisetty M, Tenenbaum JD, Suhre K, Thompson JW, St John-Williams L, MahmoudianDehkordi S, Rotroff DM, Jack JR, Motsinger-Reif A, Risacher SL, Blach C, Lucas JE, Massaro T, Louie G, Zhu HJ, Dallmann G, Klavins K, Koal T, Kim S, Nho K, Shen L, Casanova R, Varma S, Legido-Quigley C, Moseley MA, Zhu KX, Henrion MYR, van der Lee SJ, Harms AC, Demirkan A, Hankemeier T, van Duijn CM, Trojanowski JQ, Shaw LM, Saykin AJ, Weiner MW, Doraiswamy PM, Kaddurah-Daouk R, Neuroimaging AsD, Metabolomics AD. Metabolic network failures in Alzheimer’s disease: A biochemical road map. Alzheimers Dement. 2017;13(9):965-84.(2) PMID: 28341160 PMCID: PMC5866045 DOI: 10.1016/j.jalz.2017.01.020

St John-Williams L, Blach C, Toledo JB, Rotroff DM, Kim S, Klavins K, Baillie R, Han XL, Mahmoudiandehkordi S, Jack J, Massaro TJ, Lucas JE, Louie G, Motsinger-Reif AA, Risacher SL, Saykin AJ, Kastenmuller G, Arnold M, Koal T, Moseley MA, Mangravite LM, Peters MA, Tenenbaum JD, Thompson JW, Kaddurah-Daouk R, Neuroimaging AsD, Consortium AsDM. Data Descriptor: Targeted metabolomics and medication classification data from participants in the ADNI1 cohort. Nat Sci Data. 2017;4. PMID: 29039849(4) doi:  10.1038/sdata.2017.140

Beger RD, Dunn W, Schmidt MA, Gross SS, Kirwan JA, Cascante M, Brennan L, Wishart DS, Oresic M, Hankemeier T, Broadhurst DI, Lane AN, Suhre K, Kastenmüller G, Sumner SJ, Thiele I, Fiehn O, Kaddurah-Daouk R. Metabolomics enables precision medicine: “A White Paper, Community Perspective”.for “Precision Medicine and Pharmacometabolomics Task Group”-Metabolomics Society Initiative. Metabolomics. 2016;12(10):149. Epub 2016 Sep 2. PMID:27642271(5) doi:  10.1007/s11306-016-1094-6

Kim S, Nho K, Ramanan VK, Lai D, Foroud TM, Lane K, Murrell JR, Gao S, Hall KS, Unverzagt FW, Baiyewu O, Ogunniyi A, Gureje O, Kling MA, Doraiswamy PM, Kaddurah-Daouk R, Hendrie HC, Saykin AJ. Genetic Influences on Plasma Homocysteine Levels in African Americans and Yoruba Nigerians. Journal of Alzheimer’s disease : JAD. 2016;49(4):991-1003. Epub 2015/11/01. doi: 10.3233/jad-150651. PMCID: PMC4822513 DOI: 10.3233/JAD-150651

Saykin AJ, Shen L, Yao X, Kim S, Nho K, Risacher SL, Ramanan VK, Foroud TM, Faber KM, Sarwar N, Munsie LM, Hu X, Soares HD, Potkin SG, Thompson PM, Kauwe JS, Kaddurah-Daouk R, Green RC, Toga AW, Weiner MW. Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans. Alzheimers Dement. 2015;11(7):792-814. Epub 2015/07/22. doi: 10.1016/j.jalz.2015.05.009. PubMed PMID: 26194313; PMCID: PMC4510473.

Kaddurah-Daouk R, Zhu H, Sharma S, Bogdanov M, Rozen SG, Matson W, Oki NO, Motsinger-Reif AA, Churchill E, Lei Z, Appleby D, Kling MA, Trojanowski JQ, Doraiswamy PM, Arnold SE; Pharmacometabolomics Research Network. Alterations in metabolic pathways and networks in Alzheimer’s disease. Transl Psychiatry 2013 Apr 9;3:e244. doi: 10.1038/tp.2013.18. PubMed PMID: 23571809; PubMed Central PMCID: PMC3641405.

Motsinger-Reif AA, Zhu H, Kling MA, Matson W, Sharma S, Fiehn O, Reif DM, Appleby DH, Doraiswamy PM, Trojanowski JQ, Kaddurah-Daouk R, Arnold SE. Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer’s disease from normal cognitive aging. Acta Neuropathol Commun 2013 Jun 27;1(1):28. doi: 10.1186/2051-5960-1-28. PubMed PMID: 24252434; PubMed Central PMCID: PMC3893491.

Han X, Rozen S, Boyle SH, Hellegers C, Cheng H, Burke JR, Welsh-Bohmer KA, Doraiswamy PM, Kaddurah-Daouk R. Metabolomics in early Alzheimer’s disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One 2011;6(7):e21643. doi: 10.1371/journal.pone.0021643. Epub 2011 Jul 11. PubMed PMID: 21779331; PubMed Central PMCID: PMC3136924.

Kaddurah-Daouk R, Rozen S, Matson W, Han X, Hulette CM, Burke JR, Doraiswamy PM, Welsh-Bohmer KA. Metabolomic changes in autopsy-confirmed Alzheimer’s disease. Alzheimers Dement 2011 May;7(3):309-17. doi: 10.1016/j.jalz.2010.06.001. Epub 2010 Nov 13. PubMed PMID: 21075060; PubMed Central PMCID: PMC3061205.

Publications by consortium members related to metabolomics in precision medicine are listed below

Reviews:

Kaddurah-Daouk R, Weinshilboum R; Pharmacometabolomics Research Network. Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine.Clin Pharmacol Ther. 2015 Jul;98(1):71-5. doi: 10.1002/cpt.134. Epub 2015 Jun 4. PMID: 25871646

Kling MA, Trojanowski JQ, Wolk DA, Lee VM, Arnold SE. Vascular disease and dementias: paradigm shifts to drive research in new directions. Alzheimers Dement 2013 Jan;9(1):76-92. doi: 10.1016/j.jalz.2012.02.007. Epub 2012 Nov 22.  PubMed PMID: 23183137; PubMed Central PMCID: PMC3640817.

Kaddurah-Daouk R., and Weinshilboum (2014). Pharmacometabolomics: Implications for Clinical Pharmacology and Systems Pharmacology. Clin Pharmacol Ther. 2013 Nov 5. doi: 10.1038/clpt.2013.217. [Epub ahead of print]

Kaddurah-Daouk R, Krishnan KR. Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology 2009 Jan;34(1):173-86. doi: 10.1038/npp.2008.174. PubMed PMID: 18843269.

Quinones MP, Kaddurah-Daouk R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol Dis 2009 Aug;35(2):165-76. doi: 10.1016/j.nbd.2009.02.019. Epub 2009 Mar 19. PubMed PMID: 19303440.

Kaddurah-Daouk R., Kristal B.S., Weinshilboum R.M.(2008). Metabolomics: A global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol 48: 653-683.

Papers on variation of response to treatment:

Shahin MH, Gong Y, McDonough CW, Rotroff DM, Beitelshees AL, Garrett TJ, Gums JG, Motsinger-Reif A, Chapman AB, Turner ST, Boerwinkle E, Frye RF, Fiehn O, Cooper-DeHoff RM, Kaddurah-Daouk R, Johnson JA. A Genetic Response Score for Hydrochlorothiazide Use: Insights From Genomics and Metabolomics Integration. Hypertension (Dallas, Tex : 1979). 2016;68(3):621-9. Epub 2016/07/07. doi: 10.1161/hypertensionaha.116.07328. PubMed PMID: 27381900; PMCID: PMC4982802.

Rotroff DM, Oki NO, Liang X, Yee SW, Stocker SL, Corum DG, Meisner M, Fiehn O, Motsinger-Reif AA, Giacomini KM, Kaddurah-Daouk R. Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans. Frontiers in pharmacology. 2016;7:135. Epub 2016/07/06. doi: 10.3389/fphar.2016.00135. PubMed PMID: 27378919; PMCID: PMC4906013.

Rotroff DM, Corum DG, Motsinger-Reif A, Fiehn O, Bottrel N, Drevets WC, Singh J, Salvadore G, Kaddurah-Daouk R. Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants. Translational psychiatry. 2016;6(9):e894. Epub 2016/09/21. doi: 10.1038/tp.2016.145. PubMed PMID: 27648916; PMCID: PMC5048196.

Neavin D, Kaddurah-Daouk R, Weinshilboum R. Pharmacometabolomics informs Pharmacogenomics. Metabolomics. 2016;12(7). Epub 2016/08/16. doi: 10.1007/s11306-016-1066-x. PubMed PMID: 27516730; PMCID: PMC4976774.

Gupta M, Neavin D, Liu D, Biernacka J, Hall-Flavin D, Bobo WV, Frye MA, Skime M, Jenkins GD, Batzler A, Kalari K, Matson W, Bhasin SS, Zhu H, Mushiroda T, Nakamura Y, Kubo M, Wang L, Kaddurah-Daouk R, Weinshilboum RM. TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics. Molecular psychiatry. 2016;21(12):1717-25. Epub 2016/02/24. doi: 10.1038/mp.2016.6. PubMed PMID: 26903268; PMCID: PMC5003027.

de Oliveira FA, Shahin MH, Gong Y, McDonough CW, Beitelshees AL, Gums JG, Chapman AB, Boerwinkle E, Turner ST, Frye RF, Fiehn O, Kaddurah-Daouk R, Johnson JA, Cooper-DeHoff RM. Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach. Metabolomics. 2016;12(8):129. doi: 10.1007/s11306-016-1076-8.

Beger RD, Dunn W, Schmidt MA, Gross SS, Kirwan JA, Cascante M, Brennan L, Wishart DS, Oresic M, Hankemeier T, Broadhurst DI, Lane AN, Suhre K, Kastenmuller G, Sumner SJ, Thiele I, Fiehn O, Kaddurah-Daouk R. Metabolomics enables precision medicine: “A White Paper, Community Perspective”. Metabolomics. 2016;12(10):149. Epub 2016/09/20. doi: 10.1007/s11306-016-1094-6. PubMed PMID: 27642271; PMCID: PMC5009152.

Wang Z, Maity A, Hsiao CK, Voora D, Kaddurah-Daouk R, Tzeng JY. Module-based association analysis for omics data with network structure. PLoS One. 2015;10(3):e0122309. Epub 2015/03/31. doi: 10.1371/journal.pone.0122309. PubMed PMID: 25822417; PMCID: PMC4378989.

Sumner LW, Styczynski M, McLean J, Fiehn O, Jander G, Liao J, Sumner S, Britz-McKibbin P, Welti R, Jones AD, Dorrestein PC, Bearden D, Kaddurah-Daouk R. Introducing the USA Plant, Algae and Microbial Metabolomics Research Coordination Network (PAMM-NET). Metabolomics. 2015;11(1):3-5. Epub 2015/02/01. doi: 10.1007/s11306-014-0755-6. PubMed PMID: 28018159; PMCID: PMC5178969.

Rotroff DM, Shahin MH, Gurley SB, Zhu H, Motsinger-Reif A, Meisner M, Beitelshees AL, Fiehn O, Johnson JA, Elbadawi-Sidhu M, Frye RF, Gong Y, Weng L, Cooper-DeHoff RM, Kaddurah-Daouk R. Pharmacometabolomic Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response Phenotypes. CPT: pharmacometrics & systems pharmacology. 2015;4(11):669-79. doi: 10.1002/psp4.12017. PubMed PMID: 26783503; PMCID: PMC4716583

Rasmussen HB, Bjerre D, Linnet K, Jurgens G, Dalhoff K, Stefansson H, Hankemeier T, Kaddurah-Daouk R, Taboureau O, Brunak S, Houmann T, Jeppesen P, Pagsberg AK, Plessen K, Dyrborg J, Hansen PR, Hansen PE, Hughes T, Werge T. Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics. Pharmacogenomics. 2015;16(6):649-65. Epub 2015/04/22. doi: 10.2217/pgs.15.7. PubMed PMID: 25896426.

Emwas AH, Luchinat C, Turano P, Tenori L, Roy R, Salek RM, Ryan D, Merzaban JS, Kaddurah-Daouk R, Zeri AC, Nagana Gowda GA, Raftery D, Wang Y, Brennan L, Wishart DS. Standardizing the experimental conditions for using urine in NMR-based metabolomic studies with a particular focus on diagnostic studies: a review. Metabolomics. 2015;11(4):872-94. Epub 2015/06/26. doi: 10.1007/s11306-014-0746-7. PubMed PMID: 26109927; PMCID: PMC4475544.

Ellero-Simatos S, Beitelshees AL, Lewis JP, Yerges-Armstrong LM, Georgiades A, Dane A, Harms AC, Strassburg K, Guled F, Hendriks MM, Horenstein RB, Shuldiner AR, Hankemeier T, Kaddurah-Daouk R. Oxylipid Profile of Low-Dose Aspirin Exposure: A Pharmacometabolomics Study. Journal of the American Heart Association. 2015;4(10):e002203. Epub 2015/10/28. doi: 10.1161/jaha.115.002203. PubMed PMID: 26504148; PMCID: PMC4845113.

Boyle SH, Georgiades A, Brummett BH, Barefoot JC, Siegler IC, Matson WR, Kuhn CM, Grichnik K, Stafford-Smith M, Williams RB, Kaddurah-Daouk R, Surwit RS. Associations between central nervous system serotonin, fasting glucose, and hostility in African American females. Annals of behavioral medicine . 2015;49(1):49-57. Epub 2014/05/09. doi: 10.1007/s12160-014-9626-7. PubMed PMID: 24806470; PMCID: PMC4500110.

Bouhifd M, Beger R, Flynn T, Guo L, Harris G, Hogberg H, Kaddurah-Daouk R, Kamp H, Kleensang A, Maertens A, Odwin-DaCosta S, Pamies D, Robertson D, Smirnova L, Sun J, Zhao L, Hartung T. Quality assurance of metabolomics. Altex. 2015;32(4):319-26. Epub 2015/11/05. doi: 10.14573/altex.1509161. PubMed PMID: 26536290.

Studies from Pharmacometabolomics Research Network- Applications of Metabolomics in Precision Medicine

Statins:

Kaddurah-Daouk R., Baillie R.A.,  Zhu H.,  Zeng Z.B., Wiest M.M.,  Nguyen U.T., Watkins S.M.,  Krauss R.M. (2010). Lipidomic analysis of variation in response to simvastatin in the cholesterol and pharmacogenetics study. Metabolomics 6:191–201.

Kaddurah-Daouk R., Baillie R.A., Zhu H, Zeng Z.B., Wiest M.M., Nguyen U.T,  Wojnoonski K., Watkins S.M., Trupp M., Krauss R.M. (2011). Enteric Microbiome correlates with response to simvastatin treatment. PLoS One  6(10):e25482.

Trupp M, Zhu H, Wikoff WR, Baillie RA, Zeng ZB, Karp PD, Fiehn O, Krauss RM, Kaddurah-Daouk R. (2012). Metabolomics reveals amino acids contribute to variation in response to simvastatin treatment. PLoS One.;7(7):e38386. doi: 10.1371/journal.pone.0038386. Epub 2012 Jul 9.

Krauss R., Zhu H and Kaddurah-Daouk (2013). Pharmacometabolomics of statin Response. Clin Pharmacol Ther. Aug 14. doi: 10.1038

Mood disorders:

Fan T.W.M., Yuan P., Lane A.N., Higashi R.M., Wang Y., Hamidi A.B., Zhou R, Guitart Z., Chen G., Manji H.K., Kaddurah-Daouk R. (2010). Stable isotope-resolved metabolomic analysis of lithium effects on glial-neuronal metabolism and interactions. Metabolomics. 6: 165-179.

Kaddurah-Daouk R, Yuan P, Boyle SH, Matson W, Wang Z, Zeng Z, Zhu H, Dougherty GG, Yao JK, Chen G, Guitart X, Carlson PJ, Neumeister A, Zarate C, Krishnan RR, Manji HK, Drevets W. (2012). Cerebrospinal Fluid Metabolome in Mood Disorders. Science Reports  Volume 2: 667.doi: 10.1038.

Kaddurah-Daouk R, Boyle SH, Matson W, Sharma S, Matson S, Zhu H, Bogdanov MB, Churchill E,, Krishnan RR, Rush AJ, Pickering E and Delnomdedieu M. (2011). Pretreatment Metabotype as a Predictor of Response to Sertraline or Placebo in Depressed Outpatients: A Proof of Concept. Translational Psychiatry 1, Jul, 1 (7):  e26; doi:10.1038/tp.2011.22.

Kaddurah-Daouk R, Bogdanov MB, Wikoff WR, Zhu H, Boyle SH, Churchill E, Wang Z, Rush AJ, Krishnan RR, Pickering E, Delnomdedieu M, Fiehn O. (2013). Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo. Transl Psychiatry. 3:e223. doi: 10.1038/tp.2012.142.

Zhu H, Bogdanov MB, Boyle SH, Matson W, Sharma S, Matson S, Churchill E, Fiehn O, Rush JA, Krishnan RR, Pickering E, Delnomdedieu M, Kaddurah-Daouk R, Network PR. (2013). Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder – possible role for methoxyindole pathway. PLoS One. 2013 Jul 17, 8(7):e68283. doi: 10.1371.

Ji Y, Hebbring S, Zhu H, Jenkins GD, Biernacka J, Snyder K, Drews M, Fiehn O, Zeng Z, Schaid D, Mrazek DA, Kaddurah-Daouk R, Weinshilboum RM. (2011). Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther. 89(1):97-104.

Abo R, Hebbring S, Ji Y, Zhu H, Zeng ZB, Batzler A, Jenkins GD, Biernacka J, Snyder K, Drews M, Fiehn O, Fridley B, Schaid D, Kamatani N, Nakamura Y, Kubo M, Mushiroda T, Kaddurah-Daouk R, Mrazek DA, Weinshilboum RM. (2012). Merging pharmacometabolomics with pharmacogenomics using ‘1000 Genomes’ single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. Pharmacogenet Genomics. Apr;22(4):247-53.

Antihypertensives:

Wikoff W.R., Frye, R.F., Zhu, H., Boyle, S., Churchill, E., Gong, Y., Cooper-Deho , R.M., Beitelshees, A.L., Lane, A., Chapman, A.B., Turner, S.T., Fiehn, O., Johnson, J.A., Kaddurah-Daouk, R. (2013). Pharmacometabolomics Reveals Racial Differences in Response to Atenolol Treatment. March. PLoS One 3(8). e57639.

Antiplatelet Therapies:

Yerges-Armstrong LM, Ellero-Simatos S, Georgiades A, Zhu H, Lewis JP, Horenstein RB, Beitelshees AL, Dane A, Reijmers T, Hankemeier T, Fiehn O, Shuldiner AR, Kaddurah-Daouk R. (2013). Purine Pathway Implicated in Mechanism of Resistance to Aspirin Therapy: Pharmacometabolomics-Informed Pharmacogenomics. Clin Pharmacol Ther. 2013 Jun 11. doi: 10.1038.

Lewis J.P.,Yerges-Armstrong L.M., Ellero-Simatos S., Georgiades A, Kaddurah-Daouk R., and Hankemeier T (2013). Integration of Pharmacometabolomic and Pharmacogenomic Approaches Reveals Novel Insights into Antiplatelet Therapy. Clin Pharmacol Ther. Jul 26. doi: 10.1038.

Metabolomics Studies in CNS Diseases:  Our Network Experience

Yao JK, Dougherty GG, Reddy RD, Matson WR, Kaddurah-Daouk R, Keshavan MS. (2013).  Associations between purine metabolites and monoamine neurotransmitters in first-episode psychosis. Front Cell Neurosci. 2013 Jun 11;7:90. doi: 10.3389.

Perroud B, Paymaan J-N, Gatchel J.R., Wang L, Barupal D.K., Crespo-Barreto J, Fiehn O, Zoghbi H.Y., Kaddurah-Daouk R. (2013). Pharmacometabolomic Signature of Ataxia SCA1 Mouse Model and Lithium Effects. PLoS One Aug 2;8(8):e70610. doi: 10.1371.

Kaddurah-Daouk R., McEvoy J., Baillie R.A., Lee D., Yao J.K., Doraiswamy P.M., Krishnan K.R. (2007). Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry 12(10): 934-945.

Yao J.K., Dougherty G.G. Jr., Reddy R.D., Keshavan M.S., Montrose D.M., Matson W.R., Rozen S., Krishnan R.R., McEvoy J., Kaddurah-Daouk R. (2009). Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 28:1-16.

Patkar A.A., Rozen S.,  Mannelli P., Matson W., Pae C.U., Krishnan R.R., Kaddurah-Daouk R. (2009). Alterations in tryptophan and purine metabolism in cocaine addiction: A metabolomic study. Psychopharmacology (Berl) 206(3): 479-489.

Mannelli P., Patkar A., Rozen S., Matson W.R., Krishnan R., Kaddurah-Daouk R. (2009). Opioid use affects antioxidant activity and purine metabolism: Preliminary results. Hum Psychopharmacol 24(8):666-675.

Steffens D.C., Jiang W., Krishnan K.R., Karoly E.D., Mitchell M.W., O’Connor C.M., Kaddurah-Daouk R. (2010). Metabolomic differences in heart failure patients with and without major depression. J Geriatr Psychiatry Neurol 23(2):138-146.

Yao J.K., Dougherty G.G. Jr, Reddy R.D., Keshavan M.S., Montrose D.M.,Matson W.R., McEvoy J, Kaddurah-Daouk R. (2010). Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naïve patients with schizophrenia. PLoS ONE 5(3): e9508.

Condray R, Dougherty GG, Keshavan MS, Reddy RD, Haas GL, Montrose DM, Matson WR, McEvoy J, Kaddurah-Daouk R, Yao JK (2011). 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. Int J Neuropsychopharmacol. 6: 756-767.

Kaddurah-Daouk R, Rozen S, Matson W, Han X, Hulette CM, Burke JR, Doraiswamy PM, Welsh-Bohmer KA (2011). Metabolomic changes in autopsy-confirmed Alzheimer’s disease. Alzheimers Dement. 12; 7(3), 309-317.

Han X, Rozen S, Boyle SH, Hellegers C, Cheng H, Burke JR, Welsh-Bohmer KA, Doraiswamy PM, Kaddurah-Daouk  R. (2011). Metabolomics in early Alzheimer’s disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One Jul 11, 6(7): e21643.

Kaddurah-Daouk R, McEvoy J,  Baillie R,  Zhu H, Yao J, Nimgaonkar V L, Buckley PF, Keshavan MS, Georgiades A, Nasrallah HA (2012). Impaired Plasmalogens in Patients with Schizophrenia. Psychiatry Research Aug 15;198(3):347-52.

Yao JK, Condray R, Dougherty GG Jr, Keshavan MS, Montrose DM, Matson WR, McEvoy J, Kaddurah-Daouk, R, Reddy RD. (2012). Associations between purine metabolites and clinical symptoms in schizophrenia. PLoS One. 7(8):e42165. doi: 10.1371.

Kaddurah-Daouk R, Zhu H, Sharma S, Bogdanov M, Rozen SG, Matson W, Oki NO, Motsinger-Reif AA, Churchill E, Lei Z, Appleby D, Kling MA, Trojanowski JQ, Doraiswamy PM, Arnold SE; Pharmacometabolomics Research Network. (2013). Alterations in metabolic pathways and networks in mild cognitive impairment and early Alzheimer’s disease. Translational Psychiatry. 3:e244. doi: 10.1038/tp.2013.18.

Motsinger-Reif, A.A., Zhu, H., Kling, M.A., Matson, W., Sharma, S., Fiehn, O., Reif, D.M., Doraiswamy, P.M., Trajonowski, J.Q., Kaddurah-Daouk, R., Arnold, S.E. (2013). Combining metabolomic and pathologic biomarkers for discriminating early Alzheimer’s disease from normal cognitive aging. ACTA Neuropathologica Communications. 1:28.

McEvoy, J., Baillie, R.A., Zhu, H., Buckley, P., Keshavan,M.S., Nasrallah, H.A., Yao, J., and Kaddurah-Daouk, R. (2013). Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics. PLoS One. Jul 24; 8(7).doi: 10.1038/clpt.2013.153.

 

Leave a Reply

Your email address will not be published.